Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Year:
      2009
    • Author-Supplied Keywords:
      Drinking reduction
      heavy drinking
      measurement sensitivity
      naltrexone
      smoking cessation
    • NAICS/Industry Codes:
      NAICS/Industry Codes 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
      722410 Drinking Places (Alcoholic Beverages)
      621990 All other ambulatory health care services
      621999 All Other Miscellaneous Ambulatory Health Care Services
    • Abstract:
      The opiate antagonist naltrexone (Ntx) has demonstrated efficacy in the treatment of alcohol dependence and as a component of treatment to reduce heavy drinking. At present, there are no published doseranging clinical trials of the oral preparation for treatment of problem drinking. The present study evaluated the effects of Ntx on alcohol use among the subset of hazardous drinkers (n=102) who participated in a placebo-controlled, dose-ranging trial of oral Ntx (25-mg, 50-mg and 100-mg doses) combined with open-label transdermal nicotine patch for enhancing smoking cessation. On the primary outcome - no hazardous drinking (drinking that exceeded weekly or daily limits) during treatment - 25 mg and 50 mg Ntx were superior to placebo (each p<0.05). These findings remained after controlling for baseline predictors or smoking abstinence during treatment. Time to remission of hazardous drinking was examined as a secondary outcome with definitions of hazardous drinking based on weekly limits, daily limits and the combination of weekly and daily limits and the results were consistent with the primary findings. In conclusion, the findings suggest that Ntx can reduce the risk of hazardous drinking in smokers who are not seeking or receiving alcohol treatment, providing strong evidence for the pharmacological effects of Ntx on drinking. This effect appears to favour lower doses that may be better tolerated and less expensive than the higher 100-mg dose. Given its efficacy and favourable side-effect profile, the 25-mg dose should be considered for future studies of combination therapy. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of International Journal of Neuropsychopharmacology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      14611457
    • Accession Number:
      39760523
  • Citations
    • ABNT:
      O’MALLEY, S. S. et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, [s. l.], v. 12, n. 5, p. 589, 2009. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=39760523. Acesso em: 5 dez. 2020.
    • AMA:
      O’Malley SS, Krishnan-Sarin S, McKee SA, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology. 2009;12(5):589. Accessed December 5, 2020. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=39760523
    • APA:
      O’Malley, S. S., Krishnan-Sarin, S., McKee, S. A., Leeman, R. F., Cooney, N. L., Meandzija, B., Ran Wu, & Makuch, R. W. (2009). Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, 12(5), 589.
    • Chicago/Turabian: Author-Date:
      O’Malley, Stephanie S., Suchitra Krishnan-Sarin, Sherry A. McKee, Robert F. Leeman, Ned L. Cooney, Boris Meandzija, Ran Wu, and Robert W. Makuch. 2009. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology 12 (5): 589. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=39760523.
    • Harvard:
      O’Malley, S. S. et al. (2009) ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, International Journal of Neuropsychopharmacology, 12(5), p. 589. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=39760523 (Accessed: 5 December 2020).
    • Harvard: Australian:
      O’Malley, SS, Krishnan-Sarin, S, McKee, SA, Leeman, RF, Cooney, NL, Meandzija, B, Ran Wu & Makuch, RW 2009, ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, International Journal of Neuropsychopharmacology, vol. 12, no. 5, p. 589, viewed 5 December 2020, .
    • MLA:
      O’Malley, Stephanie S., et al. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology, vol. 12, no. 5, June 2009, p. 589. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=39760523.
    • Chicago/Turabian: Humanities:
      O’Malley, Stephanie S., Suchitra Krishnan-Sarin, Sherry A. McKee, Robert F. Leeman, Ned L. Cooney, Boris Meandzija, Ran Wu, and Robert W. Makuch. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology 12, no. 5 (June 2009): 589. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=39760523.
    • Vancouver/ICMJE:
      O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology [Internet]. 2009 Jun [cited 2020 Dec 5];12(5):589. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=39760523